Natco Pharma gains on expansion plans and earnings outlook
after close1 source ↓written by the desknot a recommendation
- to ₹923
- 2.5%
- previously climbing
- 5.22%
Natco Pharma's stock rose 2.5% to ₹923, previously climbing 5.22%. Rating agency ICRA reaffirmed its AA (Stable)/ A1+ ratings, highlighting the company's strong position in complex generics and R&D. The expansion into markets like Saudi Arabia and Brazil is expected to enhance profitability, despite potential litigation risks. 📈
Not investment advice. For informational purposes only.